The event aims to promote collaboration between pharmaceutical industries in both regions, and it is a component of the CELAC (Community of Latin American and Caribbean States)-EU Bi-Regional Roadmap 2022–2023, see below roadmap in 2023.

Diversification of global pharmaceutical production is essential for global health security and the EU is keen to contribute to the creation of ecosystems conducive to ensuring equitable access to quality health products.

There is a significant opportunity for cooperation between companies and important healthcare organizations in Latin America, the Caribbean and Europe. An operational roadmap has been developed containing several areas for engagement:

• private sector engagement to strengthen the region’s vaccine manufacturing capacity
• improved regional supply chains, trade integration and business environment
• regulatory strengthening
• demand consolidation and pooled procurement
• scientific cooperation
• pandemic preparedness and health security.

The EU-LAC partnership on health resilience and vaccine production is aimed at boosting local manufacturing capacities for vaccines, medicines and health technologies, as well as strengthening health systems resilience. 

To support the above objective, the European Commission organized a (virtual) marketplace and matchmaking event on pharmaceuticals from 2 February to beginning of April 2023, and a high-level forum on 21 March 2023.

The marketplace and matchmaking event consisted of an online platform where interested parties were able register and to identify potential partners and meet their counterparts through confidential Business-to-Business (B2B) sessions.

The EU-LAC pharma matchmaking initiative concluded with a high-level forum in Brussels on 21 March 2023 with the theme ‘Sharing pharmaceutical innovations between the European Union and Latin America and the Caribbean’. The scope of the forum from a products perspective included therapeutics, vaccines, generics and biosimilars. The aim was to identify synergies that meet the public health needs of Latin America and the Caribbean and EU markets.

Pharmaceutical innovations, together with higher living standards and more effective public health interventions, have been significantly important to extend life expectancy and improve population quality of life in Latin America and the Caribbean [2].

Related articles
EU public consultation on revised framework for compulsory licensing of patents

Pharmaceutical manufacturing companies in Brazil

Pharmaceutical companies in Argentina 

Market outlook for biological medicines in Brazil 2016‒2025

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Pharmaceutical companies in Latin America and the Caribbean [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Mar 31]. Available from: www.gabionline.net/generics/general/pharmaceutical-companies-in-latin-america-and-the-caribbean

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2023 Pro Pharma Communications International. All Rights Reserved.